| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e455401436df59ee149518101a72fd9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate |
2022-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab254aa0f5b46916cc042951d4daa3a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d44430b3a5b89b98cbaa5c2ff4ba120
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34718841b28667ae16c564541a510eca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_142040a1429391d37c89ade3ced16a1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fb90957517acd7743e9c2c022f309ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c659c98065e3bed914d5bca19a27fa41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeacd3c9cde2874132b3fe93ad1196e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc20aa09c5e5f832ff87203b346dc7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec2c0660e034a2005422143d19f74f97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_426ebdc267792609088610ba4bf1d787
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d5498d11eb622b52d2e200ca99caa22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e180e950de7011c0043d60cb87ffeae1 |
| publicationDate |
2022-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022185809-A1 |
| titleOfInvention |
Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
| abstract |
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021177856-A1 |
| priorityDate |
2019-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |